ERBB2 and breast carcinoma: The results of the tucatinib plus trastuzumab plus capecitabine regimen and the pyrotinib plus capecitabine regimen showed an improvement in overall response rate (ORR) in patients with HER2-positive breast cancer brain metastases (9, 10).